Abstract:We have identified a tissue-kallikrein-binding protein in human serum and in the serum-free culture media from human lung fibroblasts (WI-38) and rodent neuroblastoma X glioma hybrid cells (NG108-15). Purified and 125I-labelled tissue kallikrein and human serum form an approximately 92,000-Mr SDS-stable complex. The relative quantity of this complex-formation is measured by densitometric scanning of autoradiograms. Complex-formation between tissue kallikrein and the serum binding protein was time-dependent and detectable after 5 min incubation at 37 degrees C, with half-maximal binding at 28 min. Binding of 125I-kallikrein to kallikrein-binding protein is temperature-dependent and can be inhibited by heparin or excess unlabelled tissue kallikrein but not by plasma kallikrein, collagenase, thrombin, urokinase, alpha 1-antitrypsin or kininogens. The kallikrein-binding protein is acid- and heat-labile, as pretreatment of sera at pH 3.0 or at 60 degrees C for 30 min diminishes complex-formation. However, the formed complexes are stable to acid or 1 M-hydroxylamine treatment and can only be partially dissociated with 10 mM-NaOH. When kallikrein was inhibited by the active-site-labelling reagents phenylmethanesulphonyl fluoride or D-Phe-D-Phe-L-Arg-CH2Cl no complex-formation was observed. An endogenous approximately 92,000-Mr kallikrein-kallikrein-binding protein complex was isolated from normal human serum by using a human tissue kallikrein-agarose affinity column. These complexes were recognized by anti-(human tissue kallikrein) antibodies, but not by anti-alpha 1-antitrypsin serum, in Western-blot analyses. The results show that the kallikrein-binding protein is distinct from alpha 1-antitrypsin and is not identifiable with any of the well-characterized plasma proteinase inhibitors such as alpha 2-macroglobulin, inter-alpha-trypsin inhibitor, C1-inactivator or antithrombin III. The functional role of this kallikrein-binding protein and its impact on kallikrein activity or metabolism in vivo remain to be investigated.

Crystallization and Crystallographic Studies of Kallistatin

Crystallization and Preliminary X-ray Crystallographic Analysis of the Human CKIP-1 Pleckstrin Homology Domain.

Crystallization and Preliminary X-Ray Crystallographic Studies of Staphylokinase Variant S41g

Crystal Structure of Human Cystatin D, a Cysteine Peptidase Inhibitor with Restricted Inhibition Profile

Crystallization and Preliminary Crystallographic Analysis of Recombinant Human Calcyphosine.

Crystallization and preliminary crystallographic studies of the C-terminal domain of human FKBP52.

Crystallization and preliminary crystallographic studies of human coactosin-like protein (CLP).

Identification of a new tissue-kallikrein-binding protein

Crystallization and preliminary X-ray studies of a non-haemorrhagic fibrin(ogen)olytic metalloproteinase from the venom of Agkistrodon acutus.

Crystallization and preliminary X-ray diffraction analysis of FKBP52 N-terminal domain.

Crystallization and Preliminary Crystallographic Analysis of Human Ca 2+-Loaded Calbindin-D28k.

Crystallization and Preliminary X-ray Studies of a Non-Haemorrhagic Fibrin(ogen)olytic Metalloproteinase from the Venom Ofagkistrodon Acutus

Crystallization and preliminary crystallographic analysis of allograft inflammatory factor 1.

Crystal Structure of A Serine Protease Defines A Novel Family of Secreted Bacterial Proteases

Crystal structure of a staphylokinase: variant a model for reduced antigenicity.

Crystallization and preliminary X-ray diffraction studies of the calcium-binding protein CalD from Streptomyces coelicolor.

Crystallization and Preliminary X-ray Analysis of an Alkaline Serine Protease from Nesterenkonia Sp.

Expression, purification and preliminary crystallographic studies of human coactosin-like protein.

Purification, crystallization and preliminary crystallographic studies of a class II chitinase from kidney bean seeds.

Crystallization and crystallographic studies of human serine protease inhibitor (serpin) B9